PDS Biotechnology (NASDAQ:PDSB) Given New $13.00 Price Target at HC Wainwright

PDS Biotechnology (NASDAQ:PDSB) had its price objective trimmed by HC Wainwright from $21.00 to $13.00 in a research report released on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

PDS Biotechnology Price Performance

PDS Biotechnology stock opened at $1.26 on Thursday. The stock has a market capitalization of $48.12 million, a P/E ratio of -1.09 and a beta of 1.68. The company’s fifty day moving average price is $1.40 and its 200 day moving average price is $2.15. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. PDS Biotechnology has a 1 year low of $1.13 and a 1 year high of $4.42.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.08. As a group, equities research analysts anticipate that PDS Biotechnology will post -1.2 earnings per share for the current fiscal year.

Institutional Trading of PDS Biotechnology

Hedge funds and other institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new stake in PDS Biotechnology in the fourth quarter valued at $26,000. Jane Street Group LLC acquired a new stake in PDS Biotechnology during the 4th quarter worth approximately $58,000. Marshall Wace LLP boosted its holdings in PDS Biotechnology by 38.4% in the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock valued at $64,000 after purchasing an additional 10,837 shares during the period. Virtu Financial LLC purchased a new position in shares of PDS Biotechnology in the 4th quarter valued at about $89,000. Finally, Two Sigma Investments LP grew its holdings in PDS Biotechnology by 273.5% during the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock worth $107,000 after acquiring an additional 48,132 shares in the last quarter. 26.84% of the stock is owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.